CLINICAL USE

Treatment of urinary frequency, urgency and incontinenceNeurogenic bladder instability

DOSE IN NORMAL RENAL FUNCTION

15 mg 2–4 times a dayXL: 30 mg once daily

PHARMACOKINETICS

  • Molecular weight                           :403.9
  • %Protein binding                           :90–95
  • %Excreted unchanged in urine     : <1
  • Volume of distribution (L/kg)       :125–473 litres (Average: 279 litres)
  • half-life – normal/ESRD (hrs)      :20

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

    30–50 Dose as in normal renal function10–30 Dose as in normal renal function. Maximum 30 mg daily

  • <10           : Dose as in normal renal function. Maximum 30 mg daily

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unknown dialysability. Dose as in GFR <10 mL/min
  • HD                     :Unknown dialysability. Dose as in GFR <10 mL/min
  • HDF/high flux   :Unknown dialysability. Dose as in GFR <10 mL/min
  • CAV/VVHD      :Unknown dialysability. Dose as in GFR 10 to 20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • None known

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia